FRG1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10486(FRG1 Antibody) at dilution 1/90. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10486(FRG1 Antibody) at dilution 1/90. (Original magnification: ×200)    

  
  

The FRG1 (Facioscapulohumeral muscular dystrophy region gene 1) antibody is primarily used to study the protein encoded by the *FRG1* gene, located within the 4q35 chromosomal region linked to facioscapulohumeral muscular dystrophy (FSHD), a common hereditary muscle disorder. Although the exact role of FRG1 in FSHD pathogenesis remains debated, it is hypothesized to function in RNA processing, splicing, or transcriptional regulation. FSHD is associated with epigenetic dysregulation of the 4q35 locus, often caused by chromosomal rearrangements or D4Z4 repeat contractions, leading to aberrant expression of FRG1 and other nearby genes.

FRG1 antibodies are critical tools for detecting FRG1 protein expression in tissues or cell models, enabling research into its localization, expression levels, and interactions. Studies using these antibodies have revealed FRG1's involvement in angiogenesis, muscle development, and possible roles in mRNA transport. However, conflicting data exist; some models suggest FRG1 overexpression causes muscle pathology, while others show minimal effects, complicating its definitive link to FSHD.

Most FRG1 antibodies are generated against recombinant protein epitopes and validated for applications like Western blotting, immunohistochemistry, or immunofluorescence. Ongoing research aims to clarify FRG1's molecular mechanisms and its contribution to FSHD, with antibodies remaining essential for both diagnostic exploration and therapeutic target validation.